Apyx Medical Corp 8-K

What Happened
Apyx Medical Corporation (APYX) filed an 8-K on June 17, 2026 disclosing that on June 11, 2026 the Board appointed its Chairman, Stavros Vizirgianakis, as Executive Chairman pursuant to a letter agreement. In connection with the appointment, the Board approved a grant of 450,000 restricted stock units (RSUs) under the company’s 2023 Share Incentive Plan to recognize his service and to support his strategic leadership and governance oversight.

Key Details

• Appointment date: June 11, 2026; 8-K filed June 17, 2026.
• Total RSUs granted: 450,000 RSUs (each RSU represents a contingent right to one share).
• Vesting schedule: 150,000 RSUs vested immediately on the grant date; 150,000 RSUs begin vesting on the first anniversary and vest ratably monthly over the following 12 months; the final 150,000 RSUs begin vesting on the second anniversary and vest ratably monthly over that 12-month period. Vesting is subject to Mr. Vizirgianakis’ continued service.
• Role scope: will provide strategic leadership, governance oversight, help execute corporate initiatives, support investor engagement and advise on capital markets and corporate development. He will not be an officer or be designated an “executive officer” under Rule 3b-7 of the Exchange Act.
• RSUs are subject to the terms of the 2023 Share Incentive Plan and the letter agreement (filed as Exhibit 10.1).

Why It Matters
This filing documents a leadership arrangement and equity compensation that align the Chairman’s incentives with shareholder value through time-based RSU vesting. For investors, the appointment signals a governance and strategic advisory role for an existing board leader without making him an officer, and the RSU grant represents potential future dilution if and when shares are issued upon vesting. The vesting timetable and service condition are concrete milestones investors can track.